The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors. Abcuro announced that it has obtained $200 million in Series C financing, led by ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Ulviprubart is designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia ...

Proceeds to support completion of the registrational Phase 2/3 MUSCLE trial of ulviprubart in inclusion body myositis, BLA filing, and commercial launch preparation NEWTON, Mass.--(BUSINESS ...

Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

Rock & Roll Hall of Fame inductee and Grammy Award-winning guitarist, Peter Frampton, has unveiled a slew of additional shows ...

A founding member of Humble Pie, Frampton went on to enjoy a lengthy solo career. “Frampton Comes Alive” wasn’t just his breakthrough — it was, by light years, his largest commercial success. One of ...